Crossmark

Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes

Crossref DOI link: https://doi.org/10.1186/s12891-024-07640-6

Published Online: 2024-07-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Xianyu

Jiang, Jian

Xu, Jiajia

Chen, Jian

Gu, Yuntao

Wu, Guobao
Funding

Funding for this research was provided by:

Science and Technology Plan of Jiangxi Provincial Health Commission (SKJP220218860)
License Information

Text and Data Mining valid from 2024-07-30

Version of Record valid from 2024-07-30
More Information

Article History

Received: 15 December 2023

Accepted: 28 June 2024

First Online: 30 July 2024

Declarations

:

: All methods are reported in accordance with ARRIVE guidelines. All procedures were conducted in strict accordance with the institutional guidelines for laboratory animal treatment. The animal experiments and procedures were ethically approved by the Animal Ethics Committee of ShangRao People’s Hospital (2022-85).

: The authors declare no competing interests.

: Not applicable.

Document is current

Any future updates will be listed below